摘要：What is already known about this topic? Inadvertent exposure to the virus Vaccinia, an orthopoxvirus used in biomedical research, can cause considerable injury and time lost from work. Vaccination is recommended for laboratorians using replication-competent vaccinia virus; however, laboratories set their own policies. What is added by this report? Tecovirimat, a novel antiviral approved for treatment of smallpox, and vaccinia immunoglobulin were used to safely treat an occupational exposure in an unvaccinated laboratorian who was excluded from work for 4 months. What are the implications for public health practice? Laboratories should ensure that workers are informed of the risks associated with manipulation of vaccinia virus and should counsel workers about the potential benefits of vaccination received according to current guidelines.
